Letter to the Editor

Page 2

PCC
Do Not Overlook Bupropion Misuse
Letter to the Editor

April 30, 2024

Jasleen Kaur, MD, and colleagues comment on a case report published in the PCC.
, ,
JCP
Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?
Letter to the Editor

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...
,
PCC
Letter to the Editor

March 3, 2024

Notice of retraction for a letter to the editor.
PCC
Drug Interactions Between Psychotropic Medications and Mpox Treatment
Letter to the Editor

February 15, 2024

The authors review pharmacologic interactions of Mpox treatments with psychotropic medications and antidepressants, antipsychotics, mood stabilizers, and sedatives.
, , , et al
PCC
Intravenous Ketamine vs Intranasal Esketamine for TRD
Letter to the Editor

February 13, 2024

Dr Mansuri and colleagues compare the pros and cons of IV ketamine and intranasal esketamine for treatment-resistant depression.
, , , et al
PCC
Fentanyl-Laced Marijuana Use in Adolescents [Retracted]
Letter to the Editor

February 6, 2024

, , , et al
JCP
Reckoning Risk Retrospectively: Reply to Taipale et al
Letter to the Editor

January 22, 2024

In a reply to Taipale and colleagues, Dr Andrade discusses estimation of risk in case-control studies and in RCTs.
JCP
Relative Risk of Breast Cancer Associated With Prolactin-Increasing Antipsychotic Use
Letter to the Editor

January 22, 2024

The authors provide additional relative risk data in response to Dr Andrade’s comments on their study.
, , , et al
JCP
Testing for Sleep-Disordered Breathing in Psychiatric Practice
Letter to the Editor

January 10, 2024

Dr Barry Krakow comments on Benca and colleagues’ recent review of sleep apnea in psychiatric practice and calls for clinicians to screen for sleep-disordered breathing at intake.
PCC
Deprescribing Benzodiazepines: Is Harm Reduction Enough?
Letter to the Editor

December 28, 2023

Vania Modesto-Lowe, MD, MPH, and Claire N. Aurilio, BS, comment on a recent publication in the PCC.
,
PCC
Commentary on Catatonia and Competency to Stand Trial
Letter to the Editor

December 26, 2023

N. A. Uvais, MBBS, DPM, comments on a recent publication in the PCC.
PCC
Psychotropic-Related Sexual Dysfunction: Clinical Insights
Letter to the Editor

December 21, 2023

Clinicians should be cognizant of and avidly screen for psychotropic-related sexual dysfunction during routine follow-up clinic visits.
PCC
Insights Into Poststroke Depression
Letter to the Editor

August 31, 2023

The authors shed light on risk factors, purported mechanisms, diagnostic tips, and treatment options for poststroke depression.
,
PCC
Comment on the Midlevel Care Provider System in New York State
Letter to the Editor

August 24, 2023

This letter explores a provider type that is part of the solution to the psychiatric shortage: psychiatric pharmacists.
, ,
JCP
Safe Delivery of TMS to Patients With Implanted Devices
Letter to the Editor

July 12, 2023

Tendler et al argue that, in considering transcranial magnetic stimulation (TMS) treatment, providers should refer to recent guidelines and literature reports instead of universally excluding patients based on outdated,...
, ,
PCC
Creating Informed Interest in Mal De Débarquement Syndrome
Letter to the Editor

July 11, 2023

In this letter to the editor, Jun Maruta, PhD, and colleagues comment on a case report previously published in the PCC.
, ,
PCC
Mal de Débarquement Syndrome Complicated by Psychiatric Comorbidities: Response to Maruta et al
Letter to the Editor

July 11, 2023

Anil K. Bachu, MD, responds to Maruta and colleagues regarding a case report previously published in the PCC.
JCP
Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al
Letter to the Editor

July 3, 2023

Bénédicte Nobile, PharmD, PhD, and Philippe Courtet, MD, PhD, continue the discussion of potentially increased suicidal risk with daridorexant, a new hypnotic.
,
JCP
Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link
Letter to the Editor

July 3, 2023

Palagini and colleagues comment on a recent letter that suggested a role for daridorexant, a new hypnotic, in increasing suicide risk.
, , , et al
PCC
Comment on Palinacousis or Auditory Perseverations and COVID-19 Vaccination
Letter to the Editor

June 27, 2023

In this letter to the editor, Amnuay Kleebayoon, PhD, and Viroj Wiwanitkit, MD, comment on a report published recently in the PCC.
,
PCC
Varenicline Use for Cocaine Dependence
Letter to the Editor

May 30, 2023

In this letter to the editor, Abhishek Gupta, MBBS, reviews the latest research on the use of varenicline in cocaine dependence.
PCC
Zoom Dysmorphia and Body Dysmorphic Disorder
Letter to the Editor

April 27, 2023

In this letter to the editor, Tomás Teodoro, MD, MSc, comments on a report recently published in the PCC.
PCC
Neuropsychiatric Manifestations of Mpox
Letter to the Editor

April 18, 2023

Rujittika Mungmunpuntipantip, PhD, and Viroj Wiwanitkit, MD, comment on a report recently published in the PCC.
,
PCC
Lurasidone-Induced Urinary Retention
Letter to the Editor

April 4, 2023

Gregory M. Asnis, MD, comments on a report recently published in the PCC.

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe